Press release
DTaP Vaccine Market 2019: Global Industry Insights By Top Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Forecasts till 2026
The global DTaP Vaccine Market is expected to reach USD 5.00 Billion by 2026, according to a new report by Reports and Data. DTaP (Diphtheria, Tetanus and acellular Pertussis) is an immunization product targeting diphtheria, tetanus, and pertussis, and is usually first given at two months of age. The capital letters "D" and "P" in DTaP relate to increased diphtheria and pertussis antigen concentrations, in comparison to Tdap products.To request a sample or speak to an expert before you buy the report, click on the link below@ https://www.reportsanddata.com/sample-enquiry-form/1284
Factors such as high birth rate and the growing popularity of pertussis vaccination, are anticipated to propel the pertussis vaccine market which in turn would have a positive impact on the DTaP vaccine market globally. According to a survey by WHO in 2015, 126 countries had achieved a minimum 90% coverage of the vaccine. Besides, injuries caused by these vaccines is likely to impede the growth of the global market. In the U.S. in 2015, there had been seven claims registered in the federal VICP (Vaccine Injury Compensation Program) on account of post-pertussis vaccination injuries and deaths, comprising three deaths and four serious injuries.
Key participants include GlaxoSmithKline, Sanofi Pasteur, Protein Sciences Corporation, Novartis AG, Merch Sharp & Dohme Corp., Pfizer Inc., Astellas Pharma US, Sanofi Aventis, AstraZeneca, and Emergent Biosolution Inc. among others.
There is a growing demand for vaccines to prevent the occurrence of diseases such as diphtheria, tetanus and pertussis. These factors are projected to boost the market demand for this vaccine combination in the forecast period. Since 2012, UNICEF has obtained small quantities of DTaP vaccine for Armenia, procuring a supply from a single manufacturer. Nevertheless, since 2014, several countries, particularly MICs that usually self-procure, have expressed interest in obtaining aP-containing combination vaccines for their immunization programs through UNICEF, due to apparent difficulties in getting sufficient DTaP-containing combination vaccine supplies through their regular procurement channels.
Various initiatives being taken by governments across the globe to promote the awareness of vaccination benefits through immunization programs is projected to propel the growth of the market in the upcoming years.
For the purpose of this report, Reports and Data have segmented global DTaP Vaccine market on the basis of disease type, product type, end-user, and region:
Disease Type Outlook (Volume, Kilo Tons; 2016-2026 and Revenue, USD Million; 2016-2026)
o Diphtheria
o Tetanus
o Pertussis
Product Type Outlook (Volume, Kilo Tons; 2016-2026 and Revenue, USD Million; 2016-2026)
o Daptacel
o Infanrix
o Kinrix
o Pediarix
o Pentacel
o Quaracel
Access this report at incredible discounts by contacting us @ https://www.reportsanddata.com/discount-enquiry-form/1284
End-user Outlook (Volume, Kilo Tons; 2016-2026 and Revenue, USD Million; 2016-2026)
o Hospitals
o Clinics
o Vaccination Centers
Regional Outlook (Volume, Kilo Tons; 2016-2026 and Revenue, USD Million; 2016-2026)
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Further key findings from the report suggest
o By disease type, the use of the vaccine in treating Pertussis is anticipated to witness a significant growth rate of 7.0% during the forecast period as childhood vaccination is one of the safest and cost-effective ways for the pertussis-free environment.
o Kinrix is forecasted to hold a significant share of the market with a growth rate of 6.9% during the forecast period.
o North America contributes to the largest market share in 2018. In the U.S., coverage with DTaP vaccines differ across age groups. Vaccination coverage for children aged 19 to 35 months of age remains consistently high, at 95.0% for >=3 DTaP dosages and 84.6% for >=4 DTaP dosages reported in 2015. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S.
o The Europe and Asia Pacific markets follow the North America market in terms of market dominance.
Reasons to buy this market intelligence report:
1. Detailed market evaluation both at regional and global levels.
2. Significant changes in market scenario, along with an extensive competitive analysis
3. Classification of the industry based on product type, application, and region
4. Market segments segregated on the basis of type, application, and geography
5. Comprehensive analysis of the historical data and contemporary market scenario to infer industry size, volume, share, growth, and sales
6. Investigation of significant developments in the market dynamics
7. Market segments and regions
To purchase the complete report or selective sections, ask our expert about customization options by clicking here@ https://www.reportsanddata.com/report-detail/dtap-vaccine-market
In conclusion, the DTaP Vaccine Market report is a reliable source for accessing the Market data that will exponentially accelerate your business. The report provides the principal locale, economic scenarios with the item value, benefit, supply, limit, generation, request, Market development rate, and figure and so on. Besides, the report presents a new task SWOT analysis, speculation attainability investigation, and venture return investigation.
Contact Us:
John Watson
Head of Business Development
40 Wall St. 28th floor New York City, NY 10005 United States
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
About Us:
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release DTaP Vaccine Market 2019: Global Industry Insights By Top Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Forecasts till 2026 here
News-ID: 1945744 • Views: …
More Releases from Reports and Data

U.S. Electric Vehicle Charging Infrastructure Market Surges Toward $56.73 Billio …
The U.S. Electric Vehicle (EV) Charging Infrastructure Market reached a value of USD 5.48 billion in 2024 and is projected to surge to USD 56.73 billion by 2034, fueled by a robust CAGR of 26.1% over the period. This unprecedented growth underscores the sector's central role in decarbonizing transportation and meeting the soaring demands of electric mobility.
Market Drivers
Federal & State Policies: Major initiatives, including the Bipartisan Infrastructure Law and significant…

Automotive Refurbished Turbochargers Market to Reach USD 1.7 Billion by 2034, Dr …
The global Automotive Refurbished Turbochargers Market is set to grow from USD 0.9 billion in 2024 to USD 1.7 billion by 2034, recording a steady compound annual growth rate (CAGR) of 6.00%. This growth is being propelled by rising demand for affordable, fuel-efficient automotive solutions and stricter environmental regulations pushing the need for emission-reducing technologies.
Get Free Sample Report and Related Graphs & Charts @https://www.reportsanddata.com/sample-enquiry-form/19490
Passenger vehicles remain the largest segment of…

Automotive Powertrain Cooling System Market to Reach USD 8.2 Billion by 2034, Dr …
The global Automotive Powertrain Cooling System Market is projected to grow from USD 4.3 billion in 2024 to USD 8.2 billion by 2034, at a CAGR of 6.60%, according to the latest market study. This growth is fueled by the rising demand for fuel-efficient vehicles, increasing electric vehicle (EV) sales, and stricter global emission regulations.
Request a Sample Report with Table of Contents and Figures to click Here: @ https://www.reportsanddata.com/sample-enquiry-form/19489
Electric and…

Automotive Inverter Market to Reach USD 16.9 Billion by 2034 Driven by EV Growth
The global Automotive Inverter Market is on track for strong expansion, with forecasts projecting it will rise from USD 4.8 billion in 2024 to USD 16.9 billion by 2034, marking a compound annual growth rate (CAGR) of 13.2%. This rapid growth is being propelled by the increasing adoption of electric and hybrid vehicles, along with continued innovation in inverter technologies.
Electric vehicles (EVs) are the main driver behind this surge, as…
More Releases for DTaP
Pediatric Combination Vaccines (DTaP, Tdap, MMR, DTaP-HepB-IPV) Market Size, Cli …
Pediatric Combination Vaccines (DTaP, Tdap, MMR, DTaP-HepB-IPV) Market Size is estimated to be $7250 million in 2024 and is expected to grow at an average yearly rate of around 8% during the timeframe (2025-2032).
What is Pediatric Combination Vaccines (DTaP, Tdap, MMR, DTaP-HepB-IPV) and what are the growth drivers of Pediatric Combination Vaccines (DTaP, Tdap, MMR, DTaP-HepB-IPV) Market?
Pediatric combination vaccines are immunizations that protect children against multiple infectious diseases…
DTap-Hib-IPV Combination Vaccine Market Outlook and Future Projections for 2030
The dtap-hib-ipv combination vaccine market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the…
DTap-Hib-IPV Combination Vaccine Market Outlook and Future Projections for 2030
The dtap-hib-ipv combination vaccine market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the…
DTaP Vaccine Market Is Thriving Worldwide with GlaxoSmithKline, Sanofi, Novartis …
Advance Market Analytics added research publication document on Worldwide DTaP Vaccine Market breaking major business segments and highlighting wider level geographies to get deep dive analysis on market data. The study is a perfect balance bridging both qualitative and quantitative information of Worldwide DTaP Vaccine market. The study provides valuable market size data for historical (Volume** & Value) from 2018 to 2022 which is estimated and forecasted till 2028*. Some…
DTaP Vaccine Market | GlaxoSmithKline, Merck, Sanofi Pasteur, Ltd
The global dtap vaccine market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the dtap vaccine market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth of the…
DTaP and Tdap Vaccines Market - Development and Growth Forecast to 2028
Tdap (Tetanus, Diphtheria, Pertussis) and DTaP (Diphtheria, Tetanus, Pertussis) vaccines contain inactivated forms of the toxin generated by the bacteria that cause the three diseases. The term "inactivated forms" refers to a substance that no longer causes disease but does cause the body to develop antibodies that its immune to the toxins. DTaP is approved for children under the age of seven. Tdap, diphtheria, and pertussis vaccine with a reduced…